Global Community Acquired Pneumonia (CAP) Market Size, Status and Forecast 2019-2025

Description

Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system.
The market of CAP treatment and diagnosis in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and Latin America.
In 2018, the global Community Acquired Pneumonia (CAP) market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Community Acquired Pneumonia (CAP) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Community Acquired Pneumonia (CAP) development in United States, Europe and China.

The key players covered in this study
Pfizer
Astrazeneca
Bioaegis Therapeutics
Biotest
C10 Pharma
Kyorin Pharmaceutical
Melinta Therapeutics
Merck
Nabriva Therapeutics
Paratek Pharmaceuticals

Market segment by Type, the product can be split into
Chest X-ray/Radiography
Sputum Gram Stain and/or Culture
Blood Cultures

Market segment by Application, split into
Hospitals and Clinics
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Community Acquired Pneumonia (CAP) status, future forecast, growth opportunity, key market and key players.
To present the Community Acquired Pneumonia (CAP) development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Community Acquired Pneumonia (CAP) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

TABLE OF CONTENT

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Type (2014-2025)
1.4.2 Chest X-ray/Radiography
1.4.3 Sputum Gram Stain and/or Culture
1.4.4 Blood Cultures
1.5 Market by Application
1.5.1 Global Community Acquired Pneumonia (CAP) Market Share by Application (2014-2025)
1.5.2 Hospitals and Clinics
1.5.3 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Community Acquired Pneumonia (CAP) Market Size
2.2 Community Acquired Pneumonia (CAP) Growth Trends by Regions
2.2.1 Community Acquired Pneumonia (CAP) Market Size by Regions (2014-2025)
2.2.2 Community Acquired Pneumonia (CAP) Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Community Acquired Pneumonia (CAP) Market Size by Manufacturers
3.1.1 Global Community Acquired Pneumonia (CAP) Revenue by Manufacturers (2014-2019)
3.1.2 Global Community Acquired Pneumonia (CAP) Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Community Acquired Pneumonia (CAP) Market Concentration Ratio (CR5 and HHI)
3.2 Community Acquired Pneumonia (CAP) Key Players Head office and Area Served
3.3 Key Players Community Acquired Pneumonia (CAP) Product/Solution/Service
3.4 Date of Enter into Community Acquired Pneumonia (CAP) Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Community Acquired Pneumonia (CAP) Market Size by Type (2014-2019)
4.2 Global Community Acquired Pneumonia (CAP) Market Size by Application (2014-2019)

5 United States
5.1 United States Community Acquired Pneumonia (CAP) Market Size (2014-2019)
5.2 Community Acquired Pneumonia (CAP) Key Players in United States
5.3 United States Community Acquired Pneumonia (CAP) Market Size by Type
5.4 United States Community Acquired Pneumonia (CAP) Market Size by Application

6 Europe
6.1 Europe Community Acquired Pneumonia (CAP) Market Size (2014-2019)
6.2 Community Acquired Pneumonia (CAP) Key Players in Europe
6.3 Europe Community Acquired Pneumonia (CAP) Market Size by Type
6.4 Europe Community Acquired Pneumonia (CAP) Market Size by Application

7 China
7.1 China Community Acquired Pneumonia (CAP) Market Size (2014-2019)
7.2 Community Acquired Pneumonia (CAP) Key Players in China
7.3 China Community Acquired Pneumonia (CAP) Market Size by Type
7.4 China Community Acquired Pneumonia (CAP) Market Size by Application

8 Japan
8.1 Japan Community Acquired Pneumonia (CAP) Market Size (2014-2019)
8.2 Community Acquired Pneumonia (CAP) Key Players in Japan
8.3 Japan Community Acquired Pneumonia (CAP) Market Size by Type
8.4 Japan Community Acquired Pneumonia (CAP) Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Community Acquired Pneumonia (CAP) Market Size (2014-2019)
9.2 Community Acquired Pneumonia (CAP) Key Players in Southeast Asia
9.3 Southeast Asia Community Acquired Pneumonia (CAP) Market Size by Type
9.4 Southeast Asia Community Acquired Pneumonia (CAP) Market Size by Application

10 India
10.1 India Community Acquired Pneumonia (CAP) Market Size (2014-2019)
10.2 Community Acquired Pneumonia (CAP) Key Players in India
10.3 India Community Acquired Pneumonia (CAP) Market Size by Type
10.4 India Community Acquired Pneumonia (CAP) Market Size by Application

11 Central & South America
11.1 Central & South America Community Acquired Pneumonia (CAP) Market Size (2014-2019)
11.2 Community Acquired Pneumonia (CAP) Key Players in Central & South America
11.3 Central & South America Community Acquired Pneumonia (CAP) Market Size by Type
11.4 Central & South America Community Acquired Pneumonia (CAP) Market Size by Application

12 International Players Profiles
12.1 Pfizer
12.1.1 Pfizer Company Details
12.1.2 Company Description and Business Overview
12.1.3 Community Acquired Pneumonia (CAP) Introduction
12.1.4 Pfizer Revenue in Community Acquired Pneumonia (CAP) Business (2014-2019)
12.1.5 Pfizer Recent Development
12.2 Astrazeneca
12.2.1 Astrazeneca Company Details
12.2.2 Company Description and Business Overview
12.2.3 Community Acquired Pneumonia (CAP) Introduction
12.2.4 Astrazeneca Revenue in Community Acquired Pneumonia (CAP) Business (2014-2019)
12.2.5 Astrazeneca Recent Development
12.3 Bioaegis Therapeutics
12.3.1 Bioaegis Therapeutics Company Details
12.3.2 Company Description and Business Overview
12.3.3 Community Acquired Pneumonia (CAP) Introduction
12.3.4 Bioaegis Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2014-2019)
12.3.5 Bioaegis Therapeutics Recent Development
12.4 Biotest
12.4.1 Biotest Company Details
12.4.2 Company Description and Business Overview
12.4.3 Community Acquired Pneumonia (CAP) Introduction
12.4.4 Biotest Revenue in Community Acquired Pneumonia (CAP) Business (2014-2019)
12.4.5 Biotest Recent Development
12.5 C10 Pharma
12.5.1 C10 Pharma Company Details
12.5.2 Company Description and Business Overview
12.5.3 Community Acquired Pneumonia (CAP) Introduction
12.5.4 C10 Pharma Revenue in Community Acquired Pneumonia (CAP) Business (2014-2019)
12.5.5 C10 Pharma Recent Development
12.6 Kyorin Pharmaceutical
12.6.1 Kyorin Pharmaceutical Company Details
12.6.2 Company Description and Business Overview
12.6.3 Community Acquired Pneumonia (CAP) Introduction
12.6.4 Kyorin Pharmaceutical Revenue in Community Acquired Pneumonia (CAP) Business (2014-2019)
12.6.5 Kyorin Pharmaceutical Recent Development
12.7 Melinta Therapeutics
12.7.1 Melinta Therapeutics Company Details
12.7.2 Company Description and Business Overview
12.7.3 Community Acquired Pneumonia (CAP) Introduction
12.7.4 Melinta Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2014-2019)
12.7.5 Melinta Therapeutics Recent Development
12.8 Merck
12.8.1 Merck Company Details
12.8.2 Company Description and Business Overview
12.8.3 Community Acquired Pneumonia (CAP) Introduction
12.8.4 Merck Revenue in Community Acquired Pneumonia (CAP) Business (2014-2019)
12.8.5 Merck Recent Development
12.9 Nabriva Therapeutics
12.9.1 Nabriva Therapeutics Company Details
12.9.2 Company Description and Business Overview
12.9.3 Community Acquired Pneumonia (CAP) Introduction
12.9.4 Nabriva Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2014-2019)
12.9.5 Nabriva Therapeutics Recent Development
12.10 Paratek Pharmaceuticals
12.10.1 Paratek Pharmaceuticals Company Details
12.10.2 Company Description and Business Overview
12.10.3 Community Acquired Pneumonia (CAP) Introduction
12.10.4 Paratek Pharmaceuticals Revenue in Community Acquired Pneumonia (CAP) Business (2014-2019)
12.10.5 Paratek Pharmaceuticals Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

Choose License Type

Checkout Inquiry Sample